ABPI to Take Lead Role in Representing Vaccine Industry
News May 21, 2013
A new ABPI Vaccine Group has been formed today and will work in partnership with the public health community to support the development and implementation of successful UK immunisation programmes. The group is made up of six members - Abbott Healthcare Products Ltd, AstraZeneca, GSK, Janssen, Novartis, Pfizer.
UVIG, which has represented the vaccine industry for over a decade, has been disbanded.
Vaccinations are important because they protect the public from preventable disease, thereby helping save lives and prevent ill health whilst minimising the costs to the health service of non-immunisation. According to the World Health Organisation, vaccines help to prevent more than 2.5 million deaths each year across the world that would otherwise occur without vaccination.
Stephen Whitehead, Chief Executive of the ABPI, said:
"I am delighted that the ABPI will be taking a leading role in representing the vaccines industry to Government and other healthcare stakeholders. This addition to the ABPI strengthens the unity of the bio-pharmaceutical industry and further underlines the ABPI’s position as the leading life sciences trade association in the UK. Vaccinations against disease play a vital role in improving public health and help protect us from preventable illnesses. I am immensely proud of the work pharmaceutical companies do to bring these medicines to people across the world."
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE
Some Immune Cells May Help Tumors Instead of Destroying ThemNews
New data shows that neutrophils promote tumor progression and can actually hamper the work of immunotherapy in lung cancer.READ MORE
Oligonucleotide Drug Producers Report on Drug ImpuritiesNews
A new addition to a series of articles that focus on important topics related to the development of oligonucleotide therapeutics presents an in-depth look at the identification, characterization, and reporting of product-related impurities.READ MORE